Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: placebo
- Registration Number
- NCT00622193
- Lead Sponsor
- Helsinn Therapeutics (U.S.), Inc
- Brief Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
- Detailed Description
Cancer cachexia is a devastating, often late-stage complication of an underlying malignancy. Despite the significant importance of cancer-related cachexia, treatments are lacking and there are no products approved for this indication. Anamorelin HCl, by virtue of its ghrelin agonist activity, may serve a role in the treatment of cancer cachexia. This placebo controlled dose range study will evaluate the safety and efficacy of anamorelin HCl in patients with non-small cell lung cancer, a cancer associated with a high prevalence of cachexia.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 228
- stage IIIB or IV NSCLC
- eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab
- mixed large and small cell histologies for lung cancer
- significant obesity, BMI > 30
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Active 50 mg anamorelin HCl - 2 Active 100 mg anamorelin HCl - 3 Placebo placebo -
- Primary Outcome Measures
Name Time Method Hand grip strength and body weight Twelve weeks
- Secondary Outcome Measures
Name Time Method Quality of Life and Biomarker Twelve weeks
Trial Locations
- Locations (31)
John Hopkins University
๐บ๐ธBaltimore, Maryland, United States
SEAROC Cancer Center
๐ฎ๐ณJaipur, Rajasthan, India
University of Arkansas for Medical Sciences
๐บ๐ธLittle Rock, Arkansas, United States
The Methodist Hospital Research Institute
๐บ๐ธHouston, Texas, United States
Kodlikeri Memorial Hospital
๐ฎ๐ณMaharashtra, India
Shatabdi Super Speciality Hospital
๐ฎ๐ณMumbai Naka, Nasik, India
Augusta Oncology Associates
๐บ๐ธAugusta, Georgia, United States
Dharamshila Cancer Hospital and Research Center
๐ฎ๐ณDelhi, India
Cancer Clinic 208
๐ฎ๐ณNagpur, Maharashtra, India
South Georgia Medical Center
๐บ๐ธValdosta, Georgia, United States
Baylor College of Medicine/VAMC
๐บ๐ธHouston, Texas, United States
Caritas St. Elizabeth's Medical Center
๐บ๐ธBoston, Massachusetts, United States
Duke University Medical Center
๐บ๐ธDurham, North Carolina, United States
Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
๐ฎ๐ณPatna, Bihar, India
Birla Cancer Centre SMS Medical College Hospital
๐ฎ๐ณJaipur, India
The West Clinic
๐บ๐ธMemphis, Tennessee, United States
Osler Medical
๐บ๐ธMelbourne, Florida, United States
Investigative Clinical Research of Indiana
๐บ๐ธIndianapolis, Indiana, United States
North West Medical Specialties, PLLC
๐บ๐ธPuyallup, Washington, United States
Beth Israel Deaconess Medical Center
๐บ๐ธBoston, Massachusetts, United States
Noble Hospital
๐ฎ๐ณPune, Maharashtra, India
Massachusetts General Hospital
๐บ๐ธBoston, Massachusetts, United States
Bhagwan Mahaveer Cancer Hospital and Resaerch Center
๐ฎ๐ณJaipur, India
Jawaharlal Nehru Cancer Hospital and Research Centre
๐ฎ๐ณBhopal, India
Kamakshi Memorial Hospital
๐ฎ๐ณChennai, India
Jaslok Hospital and Research Centre
๐ฎ๐ณMumbai, India
Kaushalya Medical Foundation Trust Hospital
๐ฎ๐ณThane, Maharashtra, India
Dana Farber Cancer Center
๐บ๐ธBoston, Massachusetts, United States
Washington University School of Medicine
๐บ๐ธSt Louis, Missouri, United States
South Carolina Cancer Specialists
๐บ๐ธHilton Head Island, South Carolina, United States
Ruby Hall Clinic
๐ฎ๐ณPune, Maharashtra, India